Home › Allied-Bristol Life Sciences Launches ieCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway
 

Keywords :   


Allied-Bristol Life Sciences Launches ieCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway

2016-03-30 07:03:23| drugdiscoveryonline Home Page

Allied-Bristol Life Sciences, LLC (ABLS), a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company, announced that it has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway

Tags: the life school develop

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06Incomes have risen 'at a crawl' says think tank
28.06Are rainy days ahead for cloud computing?
28.06Electric car battery charges in under five minutes in track test
28.06Debt relief orders can write off up to 50,000
27.06Strike could force Tata plant to shut next week
27.06Eastern North Pacific Tropical Weather Outlook
27.06Atlantic Tropical Weather Outlook
27.06Texas & Southwestern Cattle Raisers Association concludes 2024 summer meeting
More »